Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
BIOCON
Mr. Shreehas Pradeep Tambe MTech · Bengaluru, India · 16,447 employees
₹431.10
▼-0.31%BIOCON's current price at 431.1 INR, trading near its 52-week high, suggests investors are optimistic about its growth prospects despite relatively low profit margins and ROE, potentially driven by its presence in the growing biotechnology sector and a buy consensus from analysts
Exchange
NSI
Currency
INR
Day range
₹427.10 – ₹435.50
52-week range
₹331.00 – ₹447.15
Sector
Healthcare
Industry
Biotechnology
AI investment rating
AI analysis70% confidence
The current price seems to be on the higher side given the P/E ratio of 153.42, suggesting that the stock might be overvalued compared to its earnings, but the company's growth prospects and industry positioning could justify the premium
3.6% below the 1-year high · trend down
Hedge-fund memo
Today
The stock is experiencing a minor correction, down 0.31% for the day, but remains near its 52-week high
This week
Short-term market sentiment appears bullish, given the proximity to the 52-week high and a strong analyst consensus
This month
Monthly gains have been slow, reflecting a consolidation phase after significant growth
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
24 headlines · 20 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
1.271 vs 1.174
8.26% surprise
2.738 vs 1.22167
124.12% surprise
0.721 vs 0.96667
-25.41% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| BIOCON | 701.96B | 153.42 | 1.15% | 15.56% | 2.30% |
| LUPIN | 1.12T | 21.02 | 26.91% | 24.22% | 31.90% |
| AUROPHARMA | 915.25B | 26.40 | 9.93% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory challenges for new products
Mitigation: Diversified product portfolio and ongoing research
Business intelligence
Competitive moat
BIOCON's competitive advantage lies in its research and development capabilities, allowing it to develop and launch new biopharmaceutical products, thereby creating a barrier to entry for new competitors
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Release of quarterly financial results
Thesis builder
Bull case
BIOCON will leverage its research capabilities to launch new biopharmaceutical products, driving growth
Base case
The company will maintain its current market position with steady revenue from existing products
Bear case
Intense competition and regulatory hurdles will hinder growth and profitability
Time horizon
Medium to long term
Est. CAGR
10-15%
Entry (qual.)
On significant dips or when valuation becomes more attractive
Exit (qual.)
If the company fails to deliver on growth expectations or faces significant regulatory setbacks
Overall conviction 70%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how BIOCON fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain BIOCON for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Investors looking for exposure to the biotechnology sector may consider accumulating BIOCON, given its diversified portfolio and growth potential, albeit with a cautious eye on valuations
IndiaMedToday·11h ago·public health initiative boosts image
Equitypandit·13h ago·first Canadian regulatory win
Sahi·14h ago·adds autoimmune indication
CNBC TV18·16h ago·multiple indications strengthen pipeline
Business Standard·16h ago·regulatory approval reinforces credibility
NewsBytes·16h ago·covers major autoimmune markets
economictimes.indiatimes.com·17h ago·consistent regulatory success
TipRanks·18h ago·high‑profile product approval
financialexpress.com·18h ago·broadens therapeutic reach
Rediff MoneyWiz·18h ago·simplified announcement of approval
scanx.trade·19h ago·reinforces market entry
InvestyWise·20h ago·official regulatory confirmation
scanx.trade·1d ago·scheduled earnings release
Whalesbook·1d ago·leadership forum enhances reputation
Whalesbook·1d ago·leadership forum enhances reputation
India CSR·1d ago·strategic health collaboration
MarketsMojo·2d ago·analyst rating not actionable
Indian Pharma Post·2d ago·stake sale signals partnership shift
TradingView·3d ago·neutral financial data listing
MarketsMojo·5d ago·neutral market activity report
Yahoo Finance Australia·5d ago·neutral price/quote info
Equitypandit·5d ago·outlook note suggests interest
livemint.com·5d ago·short‑term hype, not fundamentals
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
0.26 vs 0.775
-66.45% surprise
| 14.94% |
| 5.60% |
| GLENMARK | 638.25B | 46.85 | 14.07% | 16.30% | 14.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹427.10
Resistance (day/52w high)
₹435.50
Volume
33,51,404
Trend
down
RSI (14)
71
MACD
bullish
MA cross
golden
50-day MA
₹422.86
200-day MA
₹390.92
vs 200-DMA
10.3%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.